The aim of this commentary is to discuss the published Cochrane Review “Belimumab for systemic lupus erythematosus”1 by Singh et al.,a under the direct supervision of Cochrane Musculoskeletal Group. This Cochrane Corner is produced in agreement with International Journal of Rheumatic Diseases by Cochrane Rehabilitation
Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care...
BACKGROUND: There is limited evidence that rituximab, a B cell depletion therapy, is an effective tr...
The aim of this commentary is to discuss the published Cochrane Review “Belimumab for systemic lupu...
Background: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating protein, was the...
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentat...
Objectives: To undertake a systematic review and meta-analysis to investigate clinical effectiveness...
Elvira Bangert,1 Laura Wakani,2 Mehveen Merchant,3 Vibeke Strand,4 Zahi Touma2 1Division of Rheumato...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149757/1/art40861_am.pdfhttps://deepbl...
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by a wide ran...
OBJECTIVE: To investigate effectiveness and safety of belimumab in patients with active systemic l...
Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated autoimmune disease whi...
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentat...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
Systemic lupus erythematosus is the prototypic autoimmune disease with a broad range of clinical man...
Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care...
BACKGROUND: There is limited evidence that rituximab, a B cell depletion therapy, is an effective tr...
The aim of this commentary is to discuss the published Cochrane Review “Belimumab for systemic lupu...
Background: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating protein, was the...
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentat...
Objectives: To undertake a systematic review and meta-analysis to investigate clinical effectiveness...
Elvira Bangert,1 Laura Wakani,2 Mehveen Merchant,3 Vibeke Strand,4 Zahi Touma2 1Division of Rheumato...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149757/1/art40861_am.pdfhttps://deepbl...
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by a wide ran...
OBJECTIVE: To investigate effectiveness and safety of belimumab in patients with active systemic l...
Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated autoimmune disease whi...
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentat...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
Systemic lupus erythematosus is the prototypic autoimmune disease with a broad range of clinical man...
Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care...
BACKGROUND: There is limited evidence that rituximab, a B cell depletion therapy, is an effective tr...
DOI
Add to ORKG